Examination of lipid profile in patients with systemic lupus erythematosus: With a special focus on lipoprotein (a) in lupus nephritis;Lipidprofil vizsgálata szisztémás lupus erythematosusos betegekben, különös tekintettel a lipoprotein(a) jelentoségére lupusnephritisben

Orvosi Hetilap

Volumn 145, Issue 5, 2004, Pages 217-222

  Kiss, Emese ^a,b   Fazekas, Brigitta ^a   Tarr, Tünde ^a   Muszbek, László ^b   Zeher, Margit ^a   Szegedi, Gyula ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Klinikai Biokémiai és Molekuléris Patológiai Intézet ^*  (Hungary)

Author keywords

Cardiovascular; Lipoprotein (a); Lupus nephritis; Systemic lupus erythematosus

Indexed keywords

APOLIPOPROTEIN A1; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; LIPID; LIPOPROTEIN A;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPOPROTEINEMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIFE EXPECTANCY; LUPUS ERYTHEMATOSUS NEPHRITIS; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; ADULT; AGED; ARTICLE; BLOOD; FEMALE; KIDNEY; MALE; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; FEMALE; HUMANS; KIDNEY; LIPIDS; LIPOPROTEIN(A); LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED;

EID: 1642617660     PISSN: 00306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Aranow, C., Ginzler, E. M.: Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus, 2000, 9, 166-169.
2. Armstrong, V. W., Cremer, P., Eberle, E. és mtsai: The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis: dependence on serum LDL levels. Atherosclerosis, 1986, 62, 249-257.
3. Berg, K.: A new serum type system in man-The Lp system. Acta Pathol. Microbiol. Scand., 1963, 59, 369-382.
4. Black, I. W., Wilcken, D. E. L.: Decreases in apolipoprotein(a) after renal transplantation: Implications for lipoprotein(a) metabolism. Clin. Chem., 1992, 38, 353-357.
5. Borba E. F., Santos R. D., Bonfa E. és mtsai: Lipoprotein (A) levels in systemic lupus erythematosus. J Rheumatol., 1994, 21, 220-223.
6. Bostom, A. G., Gagnon, D. R., Cupples, L. A. és mtsai: A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women: The Framingham Heart Study. Circulation, 1994, 90, 1688-1695.
7. Cantin, B., Moorjani, S., Després, J. P. és mtsai: Lp(a) in ischemic heart disease. The Québec Cardiovascular Study. J. Am. Coll. Cardiol., 1994, 23, 481(A).
8. Cervera, R., Font, J., Paré C. és mtsai: Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann. Rheum. Dis., 1992, 51, 156-159.
9. Chapman, M. J., Huby, T., Nigon, F.: Lipoprotein(a): Implication in atherothrombosis. Atherosclerosis, 1994, 110, 69-75.
10. Esdaile, J. M., Abrahamowicz, M., Grodzicky, T.: Myocardial infarction and stroke in SLE: Markedly increased incidence after controlling for risk faktors. Arthritis Rheum., 1998, 41, SS 139.
11. Ettinger, W. H., Goldberg, A. P., Applebaum-Bowden, D.: Dyslipoproteinaemia in systemic lupus erythematosus. Effects of corticosteroids. Am. J. Med., 1987, 83, 503-508.
12. Farish, E., Rolton, H. A., Barnes J. F.: Lipoprotein(a) and postmenopausal oestrogen: Acta Endrocrinol. (Copenh), 1993, 129, 225-228.
13. Farnier, M., Bonnefous, F., Debbas, M. és mtsa: Comparative efficacy and safety of micronized fenofibrate and simvastatine in patients with primary type IIa or IIb hyperlipidaemia. Arch. Intern. Med., 1994, 154, 441-449.
14. Friedwald, W. T., Levy, R. I., Frederickson, D. S.: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem., 1972, 18, 499-502.
15. Gault, M. H., Longerich, L. L., Purchase, L. és mtsai: Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature. Nephron, 1995, 70, 155-170.
16. Hochberg, M.: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum., 1997, 40, 1725-1734.
17. Hong, S. Y., Yang, D. H.: Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrome. Nephron, 1995, 69, 125-130.
18. Hulthe, J., Wikstrand, J., Emanuelsson, H. és mtsai: Atherosclerotic changes in the carotid artery bulb as measured by B-mode ultrasound are associated with the extent of coronary atherosclerosis. Stroke, 1997, 28, 1189-1194.
19. Hwang, S. J., Ballantyne, C. M., Sharrett, A. R. és mtsai: Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ACIR) study. Circulation, 1997, 96, 4219-4225.
20. Ichikawa, T., Unoki, H., Sun, H. és mtsai: Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits. Am. J. Pathol., 2002, 160, 227-236.
21. Karádi, I., Romics, L., Palos, G. és mtsai: LP(a) lipoprotein concentriation in serum of patients with ehavy proteinuria of different origin. Clin. Chem., 1988, 35, 2121-2123.
22. Klausen, I. C., Beisiegel, U., Menzel H. J.: Apo(a) phenotypes and Lp(a) concentrations in offspring of men with and without myocardial infarction, the EARS study: Arterioscler. Thromb. Vasc. Biol., 1995, 15, 1001-1008.
23. Koshy, M., Berger, D., Crow, M. K.: Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J. Clin. Invest., 1996, 98, 826-837.
24. Kraft, H. G., Menzel, H. J., Hoppichler, F. és mtsai: Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J. Clin. Invest., 1989, 83, 137-142.
25. Kronenberg, F., Utermann, G., Dieplinger, H.: Lipoprotein(a) in renal disease. Am. J. Kidney Dis., 1996, 27, 1-25.
26. Lozada, C., Levin, R. I., Huie, M.: Identification of c1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1. Proc. Natl. Acad. Sci. USA, 1995, 92, 8378-8382.
27. MacGregor, A. J., Dhillon, V. B., Binder, A. és mtsai: Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann. Rheum. Dis., 1992, 51, 152-155.
28. Manzi, S., Meilahn, E. N., Rairie, J. és mtsai: Age-specific incidence rate of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am. J. Epidemiol., 1997, 145, 408-415.
29. Murai, A., Miyahara, T., Fujimoto, N. és mtsai: Lp(a) lipoprotein as a risk faktor for coronary heart disease and cerebral inferction. Atherosclerosis, 1986, 59, 199-204.
30. Murray, J. C, Buetow, K. H., Donovan, M. és mtsai: Linkage disequilibrium of plasminogen polymorphisms and assignment of the gene to human chromosome 6q26-6q27. Am. J. Hum. Genet., 1987, 40, 338-350.
31. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Third Report of the National Cholesterol Education Program (NECP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002, 106, 3143-3421.
32. Okawa-Takatsuji M., Aotsuka S., Sumiya M.: Clinical significance of serum lipoprotein (a) level in patients with systemic lupus erythematosus: its elevation during disease flare. Clin. Exp. Rheumatol. 1996, 14, 531-546.
33. Ordonez, J. D., Hiatt, R. A., Killebrew, E. J. és mtsa: The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int., 1993, 44, 638-642.
34. Roman, M. J., Salmon, J. E., Sobel, R. és mtsai: Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am. J. Cardiol., 2001, 87, 663-666.
35. Seed, M., Hoppichler, F., Reaveley, D. és mtsai: Relation of serum lipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterinaemia. N. Engl. J. Med., 1990, 322, 1494-1499.
36. Stenvinkel, P., Berglund, L., Heimbürger, O. és mtsai: Lipoprotein(a) in nephrotic syndrome. Kidney Int., 1993, 44, 1116-1123.
37. Sturfelt, G., Eskilsson, J., Nived, O. és mtsai: Cardiovascular disease in systemic lupus erythematosus. A study of 75 patients forms a defined population. Medicine, 1992, 71, 216-223.
38. Svenungsson, E., Jensen, K., Heimburger, M. és mtsai: Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation, 2001, 104, 1887-1893.
39. Tyrell, J., Cooke, T., Reilly, M. és mtsai: Lipoprotein(a) and peripherial vascular disease. J. Int. Med., 1992, 232, 349-352.
40. Utermann, G., Menzel, H. J., Kraft, H. G. és mtsai: Lp(a) glycoprotein phenotypes: Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J. Clin. Invest., 1987, 80, 458-465.
41. Webb, A. T., Reaveley, D. A., O'Donnell, M. és mtsai: Lipoprotein (a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol. Dial. Transplant., 1993, 8, 609-613.
42. Wilson, W. A., Gharavi, A. E., Koike, T. és mtsai: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis and Rheum., 1999, 42, 1309-1311.